Clinical trial
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting…
NCT00251277 · Weill Medical College of Cornell University, Other · Withdrawn
Key facts
| NCT number | NCT00251277 |
|---|---|
| Title | Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura |
| Official title | Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Thrombotic Thrombocytopenic Purpura |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 0 |
| Start date | Nov 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Nov 9, 2005 |
| Last update posted | Nov 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: